Mineralys Therapeutics (MLYS) Operating Expenses (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Operating Expenses data on file, last reported at $45.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 2.01% year-over-year to $45.3 million; the trailing twelve-month figure through Mar 2026 stood at $171.5 million (down 14.88% YoY), and the FY2025 full-year result was $170.6 million, down 11.33% from the prior year.
• Operating Expenses advanced to $45.3 million in Q1 2026, from $38.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $60.1 million in Q3 2024 to a low of $6.5 million in Q2 2022.
• A 5-year average of $30.9 million and a median of $35.4 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 253.94% in 2023 and sank 31.57% in 2025, its largest moves.
• Tracing MLYS's Operating Expenses over 5 years: stood at $10.0 million in 2022, then surged by 176.89% to $27.7 million in 2023, then jumped by 86.81% to $51.8 million in 2024, then retreated by 26.05% to $38.3 million in 2025, then climbed by 18.44% to $45.3 million in 2026.
• Business Quant data shows MLYS's Operating Expenses at $45.3 million in Q1 2026, $38.3 million in Q4 2025, and $41.1 million in Q3 2025.